Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer

M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshir-Rouhani-fard, Patrick Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fossa, Daniel L. Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence Einhorn, Nancy J. Cox, Lois B. Travis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs). Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt's electronic health database (BioVU) and the CALGB 90401 trial. Results: Eight sensory items formed a subscale with good internal consistency (Cronbach a =0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year, 1.06; P = 2 × 10-9), smoking (OR, 1.54; P = 0.004), excess drinking (OR, 1.83; P = 0.007), and hypertension (OR, 1.61; P = 0.03). CisIPN was correlated with lower self-reported health (OR, 0.56; P= 2.6 × 10-9) and weight gain adjusted for years since treatment (OR per Dkg/m2, 1.05; P = 0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (P value for each < 5 × 10-6) with replication of RPRD1B meeting significance criteria (Fisher combined P = 0.0089). Conclusions: CisIPN is associated with age, modifiable risk factors, and genetically determined expression level of RPRD1B. Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN.

Original languageEnglish (US)
Pages (from-to)5757-5768
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number19
DOIs
StatePublished - Oct 1 2017

Fingerprint

Peripheral Nervous System Diseases
Cisplatin
Genome
Testicular Neoplasms
Neoplasms
Drinking
Health
Smoking
Hypertension
Genome-Wide Association Study
Hypercholesterolemia
Quality Control
Genes
Weight Gain
Single Nucleotide Polymorphism
Body Mass Index
Research Design
Databases
Phenotype
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dolan, M. E., Charif, O. E., Wheeler, H. E., Gamazon, E. R., Ardeshir-Rouhani-fard, S., Monahan, P., ... Travis, L. B. (2017). Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clinical Cancer Research, 23(19), 5757-5768. https://doi.org/10.1158/1078-0432.CCR-16-3224

Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. / Dolan, M. Eileen; Charif, Omar El; Wheeler, Heather E.; Gamazon, Eric R.; Ardeshir-Rouhani-fard, Shirin; Monahan, Patrick; Feldman, Darren R.; Hamilton, Robert J.; Vaughn, David J.; Beard, Clair J.; Fung, Chunkit; Kim, Jeri; Fossa, Sophie D.; Hertz, Daniel L.; Mushiroda, Taisei; Kubo, Michiaki; Einhorn, Lawrence; Cox, Nancy J.; Travis, Lois B.

In: Clinical Cancer Research, Vol. 23, No. 19, 01.10.2017, p. 5757-5768.

Research output: Contribution to journalArticle

Dolan, ME, Charif, OE, Wheeler, HE, Gamazon, ER, Ardeshir-Rouhani-fard, S, Monahan, P, Feldman, DR, Hamilton, RJ, Vaughn, DJ, Beard, CJ, Fung, C, Kim, J, Fossa, SD, Hertz, DL, Mushiroda, T, Kubo, M, Einhorn, L, Cox, NJ & Travis, LB 2017, 'Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer', Clinical Cancer Research, vol. 23, no. 19, pp. 5757-5768. https://doi.org/10.1158/1078-0432.CCR-16-3224
Dolan, M. Eileen ; Charif, Omar El ; Wheeler, Heather E. ; Gamazon, Eric R. ; Ardeshir-Rouhani-fard, Shirin ; Monahan, Patrick ; Feldman, Darren R. ; Hamilton, Robert J. ; Vaughn, David J. ; Beard, Clair J. ; Fung, Chunkit ; Kim, Jeri ; Fossa, Sophie D. ; Hertz, Daniel L. ; Mushiroda, Taisei ; Kubo, Michiaki ; Einhorn, Lawrence ; Cox, Nancy J. ; Travis, Lois B. / Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 19. pp. 5757-5768.
@article{a5e8df629f2746128c49011fc971c8b4,
title = "Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer",
abstract = "Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs). Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt's electronic health database (BioVU) and the CALGB 90401 trial. Results: Eight sensory items formed a subscale with good internal consistency (Cronbach a =0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year, 1.06; P = 2 × 10-9), smoking (OR, 1.54; P = 0.004), excess drinking (OR, 1.83; P = 0.007), and hypertension (OR, 1.61; P = 0.03). CisIPN was correlated with lower self-reported health (OR, 0.56; P= 2.6 × 10-9) and weight gain adjusted for years since treatment (OR per Dkg/m2, 1.05; P = 0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (P value for each < 5 × 10-6) with replication of RPRD1B meeting significance criteria (Fisher combined P = 0.0089). Conclusions: CisIPN is associated with age, modifiable risk factors, and genetically determined expression level of RPRD1B. Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN.",
author = "Dolan, {M. Eileen} and Charif, {Omar El} and Wheeler, {Heather E.} and Gamazon, {Eric R.} and Shirin Ardeshir-Rouhani-fard and Patrick Monahan and Feldman, {Darren R.} and Hamilton, {Robert J.} and Vaughn, {David J.} and Beard, {Clair J.} and Chunkit Fung and Jeri Kim and Fossa, {Sophie D.} and Hertz, {Daniel L.} and Taisei Mushiroda and Michiaki Kubo and Lawrence Einhorn and Cox, {Nancy J.} and Travis, {Lois B.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-16-3224",
language = "English (US)",
volume = "23",
pages = "5757--5768",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer

AU - Dolan, M. Eileen

AU - Charif, Omar El

AU - Wheeler, Heather E.

AU - Gamazon, Eric R.

AU - Ardeshir-Rouhani-fard, Shirin

AU - Monahan, Patrick

AU - Feldman, Darren R.

AU - Hamilton, Robert J.

AU - Vaughn, David J.

AU - Beard, Clair J.

AU - Fung, Chunkit

AU - Kim, Jeri

AU - Fossa, Sophie D.

AU - Hertz, Daniel L.

AU - Mushiroda, Taisei

AU - Kubo, Michiaki

AU - Einhorn, Lawrence

AU - Cox, Nancy J.

AU - Travis, Lois B.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs). Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt's electronic health database (BioVU) and the CALGB 90401 trial. Results: Eight sensory items formed a subscale with good internal consistency (Cronbach a =0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year, 1.06; P = 2 × 10-9), smoking (OR, 1.54; P = 0.004), excess drinking (OR, 1.83; P = 0.007), and hypertension (OR, 1.61; P = 0.03). CisIPN was correlated with lower self-reported health (OR, 0.56; P= 2.6 × 10-9) and weight gain adjusted for years since treatment (OR per Dkg/m2, 1.05; P = 0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (P value for each < 5 × 10-6) with replication of RPRD1B meeting significance criteria (Fisher combined P = 0.0089). Conclusions: CisIPN is associated with age, modifiable risk factors, and genetically determined expression level of RPRD1B. Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN.

AB - Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs). Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt's electronic health database (BioVU) and the CALGB 90401 trial. Results: Eight sensory items formed a subscale with good internal consistency (Cronbach a =0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year, 1.06; P = 2 × 10-9), smoking (OR, 1.54; P = 0.004), excess drinking (OR, 1.83; P = 0.007), and hypertension (OR, 1.61; P = 0.03). CisIPN was correlated with lower self-reported health (OR, 0.56; P= 2.6 × 10-9) and weight gain adjusted for years since treatment (OR per Dkg/m2, 1.05; P = 0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (P value for each < 5 × 10-6) with replication of RPRD1B meeting significance criteria (Fisher combined P = 0.0089). Conclusions: CisIPN is associated with age, modifiable risk factors, and genetically determined expression level of RPRD1B. Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN.

UR - http://www.scopus.com/inward/record.url?scp=85032369714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032369714&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-3224

DO - 10.1158/1078-0432.CCR-16-3224

M3 - Article

VL - 23

SP - 5757

EP - 5768

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -